134P Unmasking actionable mutations in HR+/HER2–metastatic breast cancer: Real-world insights from Avida DNA OncoLiquid BiopsyNGS combined with methylation index
Federica Bini, M. Cardisperi, Rita De Sanctis, Alessandra Chirco et autres
Background: In HR+/HER2-metastatic breast cancer (MBC), ESR1 and/or PI3K pathway (PIK3CA, AKT1 and PTEN) mutations guide post-first-line therapeutic strategies.We report data on mutation prevalence in MBCs patients (pts) assessed via Avida Duo Liquid Biopsy (LB)-NGS based (Agilent Technologies) at ASST PGXXIII, Bergamo …
it (code pays fourni par la source)
0 citations
ESMO Open